Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic SEE
Time: 16:30:04
Mid Price: 1.63
Change Today: 0.00
Change % Today: 0.00
Fifty Two Week High: 3.13
Fifty Two Week Low: 1.13
Market Capital: 5.07
Period & price data
Period Price
Now: 1.63
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Technology Hardware & Equipment
Epic: SEE
News: Latest news
Web Site: Seeing Machines
Other Articles: 26-11-200906-11-200926-10-2009

Seeing Machines

Seeing Machines is engaged in the research, development and production of advanced computer vision systems for research in human performance measurement, advanced driver assistance systems, transportation, biometric acquisition, situational awareness, robotics and medical applications. Seeing Machines most advanced product is called faceLAB and provides head and face tracking, eye, eyelid and gaze tracking for human subjects within a 3-dimensional volume using a completely non-contact, video-based sensor.

CLICK HERE FOR FULL ANLAYSIS OF SEEING MACHINES
Thursday, November 26, 2009

Seeing Machines Making Transition into a More Commercially Focused Company

company news image

At its AGM, Seeing Machines (AIM: SEE) highlighted its previously reported 19% increase in full-year revenues and said it is progressing in its transition to a much more commercially focused company. The computer vision systems developer held AGM earlier today in Canberra, Australia.

Aside from the company’s revenue growth, Seeing Machines CEO Nick Cerneaz acknowledged that 2009 has been a difficult year, but emphasised the technology company’s good pipeline of opportunities. Specifically Seeing Machines took the opportunity to update investors on three key commercial developments among the group’s product applications.

Firstly the company said its DSS (Driver State Sensor) technology has made progress in strategic mining and commercial transport sectors, with significant opportunities in the sales pipeline. Seeing Machines has focused on extensive marketing and business development efforts in these sectors through the financial year and generated sales through large scale pilot deployments within resource and industrial operations.

A second major development was the launch of the TrueField Analyzer (TFA), a device for ophthalmic vision testing initially focused on the glaucoma market.  The TFA is available initially on limited release in the US.

The new faceAPI product represents the third area of development. Due to the extensive range of applications for the company’s head and eye tracking technology, Seeing Machines has developed a software development platform to enable third party developers to embed it’s technology in third party applications.

Seeing Machines said the software licensing and royalty based business model has exceeded its budgeted revenue expectations in its first full financial year since its release. The company is hopeful that it will convert a number of opportunities into new production licenses for the faceAPI and will announce further progress to the market in due course.

NewsNow icon AddThis Feed Button
Register here to be notified of future Seeing Machines articles.

Investors interested in Seeing Machines recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.